期刊文献+

支气管扩张症急性加重期患者的病原学特点 被引量:2

Analysis of the etiologyof the patients with acute exacerbating bronchiectasis
下载PDF
导出
摘要 目的分析支气管扩张症急性加重期患者的病原学特点。方法对2009~2012年的64例支气管扩张症急性加重期患者的痰培养进行回顾性分析。结果 64例患者中培养阳性34例,阳性率为53.1%;其中革兰阴性菌32株,革兰阳性菌2株,ESBLs阳性菌3株,前3位是铜绿假单胞菌18株(52.9%)、大肠埃希氏菌4株(11.8%)、肺炎克雷伯杆菌4株(11.8%)。结论支气管扩张症急性加重期患者的病原菌以G-菌特别是铜绿假单胞菌为主,应有针对性地选择对其敏感的抗菌药物,减少耐药菌的产生。 Objective To analyse the bacterial distribution of the patients with acute exacerbations of bronchiectasis. Methods We performed a retrospective investigation, 64 patients with acute exacerbations of bronchiectasis, who were hospitalized in 2009 to 2012 carried on the analysis of sputum bacterial cultivation. Results The sputum bacterial cul- tivation positive 34 cases among the 64 bronchiectasis patients (53.1%). The 32 strains of Gram-negative bacteria, 2 strains of Gram-positive bacteria, 3 strains of ESBLs positive, the top 3 are: Pseudomonas aeruginosa strain 18 (52.9%), Escherichia coli (11.8%), 4 strains of Klebsiella pneumonia in 4 strains (11.8%). Conclusion The main pathogens of bronehiectasis in patients with acute exacerbation is Gram-negative bacteria, in particular Pseudomonas aeruginosa, It should be targeted to choose their sensitive antibiotics, reduce the emergence ofresistant bacteria.
作者 武文娟
出处 《中国现代医生》 2013年第5期103-103,106,共2页 China Modern Doctor
关键词 支气管扩张症 急性加重期 病原学 Bronchiectasis Acute exacerbations Bacilliculture
  • 相关文献

参考文献5

二级参考文献39

  • 1丁震,孙耕耘,李家斌.合肥市产超广谱β-内酰胺酶菌株中OXA型ESBLs基因分布[J].中华医院感染学杂志,2005,15(2):124-126. 被引量:13
  • 2王贺,徐英春,陈民钧.细菌质粒介导的喹诺酮类抗菌药物耐药机制研究进展[J].中华医院感染学杂志,2007,17(5):618-620. 被引量:151
  • 3赵宗珉,陈佰义.抗生素轮换和替换(干预)与控制细菌耐药[J].中华内科杂志,2007,46(7):596-598. 被引量:19
  • 4Bantar C, Vesco E, Heft C, et al. Replacement of broad-spectrum cephalosporins by piperacillin-tazobactam: impact on sustained high rates of bacterial resistance. Antimierob Agents Cbemotber, 2004,48: 392-395.
  • 5Gruson D, Hilbert G, Vargas F, et al. Strategy of antibiotic rotation: long-term effect on incidence and susceptibilities of Gram negative bacilli responsible for ventilator-associated pneumonia. Crit Care Med,2003.31:1908-1914.
  • 6Bradley SJ, Wilson AL, Allen MC. et al. The control of hyperendemlc glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage. Antimicrob Chemother. 1999.43:261-266.
  • 7Li C, Nicolau DP,Lister PD, et al. Pharmacodynamic study of beta-lactams alone and in combination with beta-lactamase inhibitors against Pseudomonas aeruginosa possessing an inducible beta-lactamase. J Antimicrob Chemother, 2004, 53: 297-304.
  • 8Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev, 2001, 14 : 933- 951.
  • 9Coulton S, Francois I. Beta-Lactamases: targets of drug design. Prog Med Chem,1994,31:297-349.
  • 10Pallecchi L, Malossi M, Mantella A, et al. Detection of CTX-M- type β-lactamase genes in fecal Escherichia coil isolates from healthy children in Bolivia and Peru. Antimicrob Agents Chemother, 2004.48 :4556-4561.

共引文献1844

同被引文献10

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部